Clinical drug investigation

Keyphrases

Publications

volume 44, number 6, 2024

Pamela Delgado-García, Juan Bautista Alcocer-Herrera, Adelfia Urenda-Quezada, María Dolores Alonso-Martinez, María Arcelia Bautista-Mendoza, Yulia Romero-Antonio, Julio C Mora-Villalobos, José G Sander-Padilla, Kevin F Rios-Brito, Ileana C Rodríguez-Vázquez, Jorge Gonzalez-Canudas
A Randomized Control Trial of Dexketoprofen/Vitamin B (Thiamine, Pyridoxine and Cyanocobalamin) Fixed-Dose Combination in Post-Traumatic Grade I-II Cervical Sprains. Clinical drug investigation 44 (6) (2024)
Pamela Delgado-García, Juan Bautista Alcocer-Herrera, Adelfia Urenda-Quezada, María Dolores Alonso-Martinez, María Arcelia Bautista-Mendoza, Yulia Romero-Antonio, Julio C Mora-Villalobos, José G Sander-Padilla, Kevin F Rios-Brito, Ileana C Rodríguez-Vázquez, Jorge Gonzalez-Canudas
A Randomized Control Trial of Dexketoprofen/Vitamin B (Thiamine, Pyridoxine and Cyanocobalamin) Fixed-Dose Combination in Post-Traumatic Grade I-II Cervical Sprains. Clinical drug investigation 44 (6) (2024)
Yoshifumi Miyagi, Satoru Iwashima
Prediction Models for Intravenous Immunoglobulin Non-Responders of Kawasaki Disease Using Machine Learning. Clinical drug investigation 44 (6) (2024)
Pablo E Bretos-Azcona, Matthew Wallace, Murvin Jootun, Guanyi Jin, Ion Agirrezabal, Agota Szende
An Early Cost-Utility Model of mRNA-Based Therapies for the Treatment of Methylmalonic and Propionic Acidemia in the United Kingdom. Clinical drug investigation 44 (6) (2024)
John E Hughes, Kathleen E Bennett, Caitriona Cahir
Drug-Drug Interactions and Their Association with Adverse Health Outcomes in the Older Community-Dwelling Population: A Prospective Cohort Study. Clinical drug investigation 44 (6) (2024)
Yu-Wei Qiao, Guo Yu, Guo-Fu Li
Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail. Clinical drug investigation 44 (6) (2024)
Lei Dong, Jianxing Xiang, Michael Babcock, Yuanzhi Cheng, Yan Wang, Yuqiao Shen, Li Li, Liping Tan, Marvin Garovoy, Wei Hu, Jianhong Zheng
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers. Clinical drug investigation 44 (6) (2024)
Chen Gu Niu, Jing Zhang, Mahesh Napel, Leela Krishna Teja Boppana, Hashem Anas, Nagesh Jadhav, Karin Dunnigan, Patrick I Okolo
Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis. Clinical drug investigation 44 (6) (2024)
John E Hughes, Kathleen E Bennett, Caitriona Cahir
Drug-Drug Interactions and Their Association with Adverse Health Outcomes in the Older Community-Dwelling Population: A Prospective Cohort Study. Clinical drug investigation 44 (6) (2024)

volume 44, number 7, 2024

Masaki Fukuda, Junko Hattori, Rika Ohkubo, Asuka Watanabe, Shinichiroh Maekawa
Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan. Clinical drug investigation 44 (7) (2024)
Masaki Fukuda, Junko Hattori, Rika Ohkubo, Asuka Watanabe, Shinichiroh Maekawa
Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan. Clinical drug investigation 44 (7) (2024)
M V T Krishna Mohan, Arpitkumar Prajapati, Rushabh Kothari, Srikrishna Mandal, Ranganatha Rao Srikanth, Rajnish Nagarkar, Shriram Khane, Ayyagari Santa, Disha Dadke
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Clinical drug investigation 44 (7) (2024)
Hannah A Blair
AVT04: An Ustekinumab Biosimilar. Clinical drug investigation 44 (7) (2024)
Renjie Gao, Panpan Zhao, Kai Yan
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Parkinson's Disease: A Systematic Review and Meta-Analysis. Clinical drug investigation 44 (7) (2024)
Arsh Ketabforoush, Faezeh Faghihi, Fereshteh Azedi, Armin Ariaei, Mohamad Amin Habibi, Maryam Khalili, Bahram Haghi Ashtiani, Mohammad Taghi Joghataei, William David Arnold
Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment. Clinical drug investigation 44 (7) (2024)
Hannah A Blair
AVT04: An Ustekinumab Biosimilar. Clinical drug investigation 44 (7) (2024)
Masaki Fukuda, Junko Hattori, Rika Ohkubo, Asuka Watanabe, Shinichiroh Maekawa
Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan. Clinical drug investigation 44 (7) (2024)
Masaki Fukuda, Junko Hattori, Rika Ohkubo, Asuka Watanabe, Shinichiroh Maekawa
Real-World Safety and Effectiveness of Letermovir in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation: Final Results of Post-Marketing Surveillance in Japan. Clinical drug investigation 44 (7) (2024)
M V T Krishna Mohan, Arpitkumar Prajapati, Rushabh Kothari, Srikrishna Mandal, Ranganatha Rao Srikanth, Rajnish Nagarkar, Shriram Khane, Ayyagari Santa, Disha Dadke
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Clinical drug investigation 44 (7) (2024)
M V T Krishna Mohan, Arpitkumar Prajapati, Rushabh Kothari, Srikrishna Mandal, Ranganatha Rao Srikanth, Rajnish Nagarkar, Shriram Khane, Ayyagari Santa, Disha Dadke
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Clinical drug investigation 44 (7) (2024)
Arsh Ketabforoush, Faezeh Faghihi, Fereshteh Azedi, Armin Ariaei, Mohamad Amin Habibi, Maryam Khalili, Bahram Haghi Ashtiani, Mohammad Taghi Joghataei, William David Arnold
Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment. Clinical drug investigation 44 (7) (2024)
Hannah A Blair
AVT04: An Ustekinumab Biosimilar. Clinical drug investigation 44 (7) (2024)
Hannah A Blair
AVT04: An Ustekinumab Biosimilar. Clinical drug investigation 44 (7) (2024)
Renjie Gao, Panpan Zhao, Kai Yan
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Parkinson's Disease: A Systematic Review and Meta-Analysis. Clinical drug investigation 44 (7) (2024)
Ali Azargoonjahromi
Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. Clinical drug investigation 44 (7) (2024)
Arsh Ketabforoush, Faezeh Faghihi, Fereshteh Azedi, Armin Ariaei, Mohamad Amin Habibi, Maryam Khalili, Bahram Haghi Ashtiani, Mohammad Taghi Joghataei, William David Arnold
Sodium Phenylbutyrate and Tauroursodeoxycholic Acid: A Story of Hope Turned to Disappointment in Amyotrophic Lateral Sclerosis Treatment. Clinical drug investigation 44 (7) (2024)
Erika Martinelli, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Sara Del Tufo, Luca D'Ambrosio, Marco De Chiara, Vincenzo Famiglietti, Valeria Nacca, Claudia Cardone, Antonio Avallone, Chiara Cremolini, Filippo Pietrantonio, Evaristo Maiello, Vincenza Granata, Teresa Troiani, Salvatore Cappabianca, Fortunato Ciardiello, Valerio Nardone, Alfonso Reginelli
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial. Clinical drug investigation 44 (7) (2024)
Hannah A Blair
AVT04: An Ustekinumab Biosimilar. Clinical drug investigation 44 (7) (2024)
M V T Krishna Mohan, Arpitkumar Prajapati, Rushabh Kothari, Srikrishna Mandal, Ranganatha Rao Srikanth, Rajnish Nagarkar, Shriram Khane, Ayyagari Santa, Disha Dadke
Efficacy and Safety of BP02 (Trastuzumab Biosimilar) in HER2-Positive Metastatic Breast Cancer: A Multicenter Phase III Study. Clinical drug investigation 44 (7) (2024)
Ali Azargoonjahromi
Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. Clinical drug investigation 44 (7) (2024)
Erika Martinelli, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Sara Del Tufo, Luca D'Ambrosio, Marco De Chiara, Vincenzo Famiglietti, Valeria Nacca, Claudia Cardone, Antonio Avallone, Chiara Cremolini, Filippo Pietrantonio, Evaristo Maiello, Vincenza Granata, Teresa Troiani, Salvatore Cappabianca, Fortunato Ciardiello, Valerio Nardone, Alfonso Reginelli
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial. Clinical drug investigation 44 (7) (2024)
Renjie Gao, Panpan Zhao, Kai Yan
Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Parkinson's Disease: A Systematic Review and Meta-Analysis. Clinical drug investigation 44 (7) (2024)

volume 44, number 8, 2024

Nobuko Matsushima, Sayori Shibata, Jocelyn H Leu, An Vermeulen, Jay Duffner, Leona E Ling, Lisa B Schwartz, Hideo Harigae
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers. Clinical drug investigation 44 (8) (2024)
Cataldo Patruno, Giuseppe Lauletta, Elena Pezzolo, Valeria Boccaletti, Mariateresa Rossi, Francesca Caroppo, Anna Belloni Fortina, Filomena Russo, Barbara Cocuroccia, Giacomo Dal Bello, Fabrizio Martora, Francesca di Vico, Maddalena Napolitano
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting. Clinical drug investigation 44 (8) (2024)
Martina Paoletti, Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini
Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy. Clinical drug investigation 44 (8) (2024)
Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan-Vidal, Teresa López-Fernández, Ernest Nadal, Delvys Rodríguez-Abreu, María Vares, Úrsula Asensio, Luis F García, Enriqueta Felip
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clinical drug investigation 44 (8) (2024)
Nobuko Matsushima, Sayori Shibata, Jocelyn H Leu, An Vermeulen, Jay Duffner, Leona E Ling, Lisa B Schwartz, Hideo Harigae
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers. Clinical drug investigation 44 (8) (2024)
Khadidja Abdallah, Isabelle Huys, Kathleen J Claes, Steven R A Simoens
Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease. Clinical drug investigation 44 (8) (2024)
Nobuko Matsushima, Sayori Shibata, Jocelyn H Leu, An Vermeulen, Jay Duffner, Leona E Ling, Lisa B Schwartz, Hideo Harigae
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers. Clinical drug investigation 44 (8) (2024)
Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan-Vidal, Teresa López-Fernández, Ernest Nadal, Delvys Rodríguez-Abreu, María Vares, Úrsula Asensio, Luis F García, Enriqueta Felip
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clinical drug investigation 44 (8) (2024)
Irene Dell'Anno, Leonardo Dondi, Immacolata Esposito, Annamaria Mascolo, Annalisa Capuano, Giulia de Marchi, Adriano Cristinziano, Domenico Tarantino, Marcello Pani, Carla Masini, Caterina Donati, Elisabetta Rossin, Antonio Serafini, Gabriele Bagaglini, Gabriella Bonanni, Tommaso Gregori, Arturo Cavaliere, Roberta Matocci, Alessandro D'Arpino, Nello Martini, Carlo Piccinni
The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O. Clinical drug investigation 44 (8) (2024)
Martina Paoletti, Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini
Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy. Clinical drug investigation 44 (8) (2024)
Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan-Vidal, Teresa López-Fernández, Ernest Nadal, Delvys Rodríguez-Abreu, María Vares, Úrsula Asensio, Luis F García, Enriqueta Felip
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clinical drug investigation 44 (8) (2024)
Khadidja Abdallah, Isabelle Huys, Kathleen J Claes, Steven R A Simoens
Budget Impact of Disease-Modifying Treatments and a CRISPR Gene-Edited Therapy for Sickle Cell Disease. Clinical drug investigation 44 (8) (2024)
Cataldo Patruno, Giuseppe Lauletta, Elena Pezzolo, Valeria Boccaletti, Mariateresa Rossi, Francesca Caroppo, Anna Belloni Fortina, Filomena Russo, Barbara Cocuroccia, Giacomo Dal Bello, Fabrizio Martora, Francesca di Vico, Maddalena Napolitano
Effectiveness and Safety of Upadacitinib for Adolescents with Atopic Dermatitis in a Real-World Setting. Clinical drug investigation 44 (8) (2024)
Martina Paoletti, Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini
Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy. Clinical drug investigation 44 (8) (2024)
Nobuko Matsushima, Sayori Shibata, Jocelyn H Leu, An Vermeulen, Jay Duffner, Leona E Ling, Lisa B Schwartz, Hideo Harigae
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers. Clinical drug investigation 44 (8) (2024)
Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan-Vidal, Teresa López-Fernández, Ernest Nadal, Delvys Rodríguez-Abreu, María Vares, Úrsula Asensio, Luis F García, Enriqueta Felip
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clinical drug investigation 44 (8) (2024)
Irene Dell'Anno, Leonardo Dondi, Immacolata Esposito, Annamaria Mascolo, Annalisa Capuano, Giulia de Marchi, Adriano Cristinziano, Domenico Tarantino, Marcello Pani, Carla Masini, Caterina Donati, Elisabetta Rossin, Antonio Serafini, Gabriele Bagaglini, Gabriella Bonanni, Tommaso Gregori, Arturo Cavaliere, Roberta Matocci, Alessandro D'Arpino, Nello Martini, Carlo Piccinni
The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O. Clinical drug investigation 44 (8) (2024)
Martina Paoletti, Chiara Bini, Andrea Marcellusi, Francesco Saverio Mennini
Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy. Clinical drug investigation 44 (8) (2024)